Topoisomerase I inhibition in colorectal cancer: biomarkers and therapeutic targets

To live or to die: a matter of processing damaged DNA termini in neurons

(2011) Sherif F. El-Khamisy   EMBO Molecular Medicine

Preoperative Chemoradiotherapy Using Concurrent Capecitabine and Irinotecan in Magnetic Resonance Imaging–Defined Locally Advanced Rectal Cancer: Impact on Long-Term Clinical Outcomes

(2011) Simon Gollins et al.   JOURNAL OF CLINICAL ONCOLOGY

New Topoisomerase I mutations are associated with resistance to camptothecin

(2011) Céline Gongora et al.   Molecular Cancer

Poly(ADP-ribose) polymerase and XPF–ERCC1 participate in distinct pathways for the repair of topoisomerase I-induced DNA damage in mammalian cells

(2011) Yong-Wei Zhang et al.   NUCLEIC ACIDS RESEARCH

Topoisomerase I expression correlates to response to neoadjuvant irinotecan-based chemoradiation in rectal cancer

(2010) Karoline Horisberger et al.   ANTI-CANCER DRUGS

Targeting the p38 MAPK Pathway Inhibits Irinotecan Resistance in Colon Adenocarcinoma

(2010) S. Paillas et al.   CANCER RESEARCH

Poly(ADP-Ribose) Polymerase Inhibitor Induces Accelerated Senescence in Irradiated Breast Cancer Cells and Tumors

(2010) E. V. Efimova et al.   CANCER RESEARCH

TDP1 serine 81 promotes interaction with DNA ligase IIIα and facilitates cell survival following DNA damage

(2010) Shih-Chieh Chiang et al.   CELL CYCLE

Aprataxin Tumor Levels Predict Response of Colorectal Cancer Patients to Irinotecan-based Treatment

(2010) H. Dopeso et al.   CLINICAL CANCER RESEARCH

Novel therapeutics in combination with radiotherapy to improve cancer treatment: Rationale, mechanisms of action and clinical perspective

(2010) Marcel Verheij et al.   DRUG RESISTANCE UPDATES

Camptothecins Compared with Etoposide in Combination with Platinum Analog in Extensive Stage Small Cell Lung Cancer: Systematic Review with Meta-Analysis

(2010) João Paulo S.N. Lima et al.   Journal of Thoracic Oncology

Poly(ADP-Ribose) Polymerase Inhibition as a Model for Synthetic Lethality in Developing Radiation Oncology Targets

(2010) Anthony J. Chalmers et al.   SEMINARS IN RADIATION ONCOLOGY

Synergistic decrease of DNA single-strand break repair rates in mouse neural cells lacking both Tdp1 and aprataxin

(2009) Sherif F. El-Khamisy et al.   DNA REPAIR

Tyrosyl-DNA phosphodiesterase and the repair of 3′-phosphoglycolate-terminated DNA double-strand breaks

(2009) Tong Zhou et al.   DNA REPAIR

6003 The correlation between Topoisomerase-I (Topo1) expression and outcome of treatment with capecitabine and irinotecan in advanced colorectal cancer (ACC) patients (pts) treated in the CAIRO study of the Dutch Colorectal Cancer Group (DCCG)

(2009) M. Koopman et al.   EJC SUPPLEMENTS

Microsatellite Instability Predicts Improved Response to Adjuvant Therapy With Irinotecan, Fluorouracil, and Leucovorin in Stage III Colon Cancer: Cancer and Leukemia Group B Protocol 89803

(2009) Monica M. Bertagnolli et al.   JOURNAL OF CLINICAL ONCOLOGY

Predictive Role of the UGT1A1, UGT1A7, and UGT1A9 Genetic Variants and Their Haplotypes on the Outcome of Metastatic Colorectal Cancer Patients Treated With Fluorouracil, Leucovorin, and Irinotecan

(2009) Erika Cecchin et al.   JOURNAL OF CLINICAL ONCOLOGY

New specific molecular targets for radio-chemotherapy of rectal cancer

(2009) Kristin Snipstad et al.   Molecular Oncology

A human 5′-tyrosyl DNA phosphodiesterase that repairs topoisomerase-mediated DNA damage

(2009) Felipe Cortes Ledesma et al.   NATURE

Pharmacodynamic genes do not influence risk of neutropenia in cancer patients treated with moderately high-dose irinotecan

(2009) Janelle M Hoskins et al.   PHARMACOGENOMICS

Irinotecan Pharmacogenetics: Influence of Pharmacodynamic Genes

(2008) J. M. Hoskins et al.   CLINICAL CANCER RESEARCH

Predictive Biomarkers of Chemotherapy Efficacy in Colorectal Cancer: Results From the UK MRC FOCUS Trial

(2008) Michael S. Braun et al.   JOURNAL OF CLINICAL ONCOLOGY

Copy-number analysis of topoisomerase and thymidylate synthase genes in frozen and FFPE DNAs of colorectal cancers

(2008) Jinsheng Yu et al.   PHARMACOGENOMICS